HK Stock Market Move | VIGONVITA-B(02630) rose more than 15% in the afternoon. Recently, a licensing agreement was reached with SIMCERE PHARMA on the new indication for VV116.

VIGONVITA-B (02630) rose more than 15% in the afternoon, closing at a 14.81% increase to 88 Hong Kong dollars, with a turnover of 133.12 million Hong Kong dollars. On the news front, VastSense announced earlier this month that it has entered into a licensing agreement with SIMCERE PHARMA for the new indication of VV116. According to the agreement, SIMCERE PHARMA will obtain exclusive rights to use Deutiramide hydrobromide suspension in the Greater China region for the treatment of respiratory syncytial virus (RSV) infections and human metapneumovirus (HMPV) infections. VastSense and SIMCERE PHARMA are joining forces to leverage their respective research and development, manufacturing, and commercialization advantages to accelerate the clinical development and commercialization process of VV116, in order to benefit more patients. Public information shows that VastSense focuses on three major treatment areas: neurology and psychiatry, reproductive health, and viral infections. As of October 21, 2025, the company has established a diversified pipeline of 9 innovative products, with 2 in the commercialization stage, 4 in the clinical stage, and 3 in the preclinical stage. In addition to the innovative drug pipeline, the company also has a portfolio of generic drugs, with 3 drugs in the commercialization or near-commercialization stage. Currently, VastSense's two core products are LV232 and TPN171.